Short-and long-term safety of oral propranolol in the treatment of infantile hemangioma
10.3760/cma.j.issn.0412-4030.2019.08.019
- VernacularTitle:口服普萘洛尔治疗婴儿血管瘤的近期和远期安全性
- Author:
Lu YU
1
;
Li LI
;
Lin MA
Author Information
1. 首都医科大学附属北京儿童医院皮肤科 100045
- Keywords:
Hemangioma;
Propranolol;
Infant;
Long-term safety;
Short-term safety
- From:
Chinese Journal of Dermatology
2019;52(8):586-589
- CountryChina
- Language:Chinese
-
Abstract:
Infantile hemangioma is the most common tumor in infancy,with an incidence of 4％-5％.According to the risk level,hemangioma is divided into 3 levels:high risk,medium risk and low risk.At present,the first-line treatment of high-risk hemangioma is oral propranolol (β-receptor blockers).It has been 10 years since infantile hemangioma was treated with propranolol for the first time,and propranolol has been the drug of first-choice in systematic treatment due to its high efficacy and good safety,but its long-term adverse effect needs further evaluation.
